Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions

Lung Cancer

Interventions

DRUG

Abemaciclib

Abemaciclib 150mg BID

DRUG

Osimertinib

Osimertinib 80mg daily

Trial Locations (1)

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of California, San Diego

OTHER